107 related articles for article (PubMed ID: 26912826)
1. Etiological Observations in Seven Patients with Pancreatic Neuroendocrine Tumors (PNETs).
Landin J; Weber W
In Vivo; 2016; 30(2):147-8. PubMed ID: 26912826
[TBL] [Abstract][Full Text] [Related]
2. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.
Ito T; Lee L; Hijioka M; Kawabe K; Kato M; Nakamura K; Ueda K; Ohtsuka T; Igarashi H
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):574-7. PubMed ID: 25689058
[TBL] [Abstract][Full Text] [Related]
3. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 1β gene single-nucleotide polymorphisms and susceptibility to pancreatic neuroendocrine tumors.
Cigrovski Berković M; Catela Ivković T; Marout J; Zjačić-Rotkvić V; Kapitanović S
DNA Cell Biol; 2012 Apr; 31(4):531-6. PubMed ID: 21988351
[TBL] [Abstract][Full Text] [Related]
5. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic neuroendocrine tumors: a review.
Young K; Iyer R; Morganstein D; Chau I; Cunningham D; Starling N
Future Oncol; 2015; 11(5):853-64. PubMed ID: 25757686
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumors of the pancreas.
Ehehalt F; Saeger HD; Schmidt CM; Grützmann R
Oncologist; 2009 May; 14(5):456-67. PubMed ID: 19411317
[TBL] [Abstract][Full Text] [Related]
8. National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors.
Kasumova GG; Tabatabaie O; Eskander MF; Tadikonda A; Ng SC; Tseng JF
J Am Coll Surg; 2017 Jun; 224(6):1057-1064. PubMed ID: 27965134
[TBL] [Abstract][Full Text] [Related]
9. Cystic pancreatic neuroendocrine tumors: outcomes of preoperative endosonography-guided fine needle aspiration, and recurrence during long-term follow-up.
Ridtitid W; Halawi H; DeWitt JM; Sherman S; LeBlanc J; McHenry L; Coté GA; Al-Haddad MA
Endoscopy; 2015 Jul; 47(7):617-25. PubMed ID: 25763832
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.
Halfdanarson TR; Bamlet WR; McWilliams RR; Hobday TJ; Burch PA; Rabe KG; Petersen GM
Pancreas; 2014 Nov; 43(8):1219-22. PubMed ID: 25291526
[TBL] [Abstract][Full Text] [Related]
11. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors.
Qadan M; Ma Y; Visser BC; Kunz PL; Fisher GA; Norton JA; Poultsides GA
J Am Coll Surg; 2014 Feb; 218(2):188-95. PubMed ID: 24321190
[TBL] [Abstract][Full Text] [Related]
12. Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).
Jung JG; Lee KT; Woo YS; Lee JK; Lee KH; Jang KT; Rhee JC
Medicine (Baltimore); 2015 Jul; 94(26):e983. PubMed ID: 26131843
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study.
Ben Q; Zhong J; Fei J; Chen H; Yv L; Tan J; Yuan Y
Sci Rep; 2016 Oct; 6():36073. PubMed ID: 27782199
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas.
Karaman K; Bostanci EB; Aksoy E; Kurt M; Celep B; Ulas M; Dalgic T; Surmelioglu A; Hayran M; Akoglu M
Eur J Intern Med; 2011 Dec; 22(6):e95-8. PubMed ID: 22075321
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience.
Oleinikov K; Uri I; Jacob H; Epshtein J; Benson A; Ben-Haim S; Atlan K; Tal I; Meirovitz A; Maimon O; Lev-Cohain N; Mazeh H; Glaser B; Gross DJ; Grozinsky-Glasberg S
Endocrine; 2020 Apr; 68(1):222-229. PubMed ID: 32036501
[TBL] [Abstract][Full Text] [Related]
16. Potential value of EUS in pancreatic surveillance of VHL patients.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Koopmans KP; Kema IP; Zonnenberg BA; Timmers HJ; de Herder WW; Sluiter WJ; de Vries EG; Links TP
Eur J Endocrinol; 2016 May; 174(5):611-20. PubMed ID: 26884551
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome.
Dʼsouza SL; Elmunzer BJ; Scheiman JM
J Clin Gastroenterol; 2014; 48(5):458-61. PubMed ID: 24356459
[TBL] [Abstract][Full Text] [Related]
18. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
Liu IH; Ford JM; Kunz PL
Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.
Mpilla GB; Philip PA; El-Rayes B; Azmi AS
World J Gastroenterol; 2020 Jul; 26(28):4036-4054. PubMed ID: 32821069
[TBL] [Abstract][Full Text] [Related]
20. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
